Merck & Co. recently suspended discussions to acquire Revolution Medicines after both parties failed to reach agreement on a buyout valuation that had been speculated to be in the tens of billions. People familiar with the matter indicate that Merck’s decision reflects the company’s disciplined approach to deal size, even as it seeks to bolster its oncology pipeline. While discussions could theoretically resume, Merck has shifted focus back to internal R&D and smaller bolt-on transactions.

During the third quarter, Cullen/Frost Bankers Inc. reduced its Merck stake by 7.0%, selling 17,082 shares and bringing its holding to 225,581 shares. In the second quarter, Charles Schwab Investment Management increased its position by 9.4%, acquiring 4.6 million additional shares, while DLD Asset Management and Norges Bank each initiated new positions worth roughly $2.8 billion. Franklin Resources grew its stake by 23.5%, adding 5.1 million shares, and Fisher Asset Management boosted its holding by 2.3%. Together, institutional ownership of Merck stands at approximately 76% of the float.

In its latest quarter, Merck reported adjusted earnings per share of $1.94, falling short of consensus estimates by $0.14, yet delivered a net margin of 29.6% and return on equity of 44.5%. The company announced a 5% increase in its quarterly dividend to $0.85 per share, reflecting strong free-cash-flow generation and a payout ratio of roughly 45%. Management reiterated guidance for the full year and underscored continued investment in key growth drivers such as Keytruda and its vaccine portfolio.

Following the earnings release, BMO Capital Markets upgraded Merck to “Outperform,” raising its price target to $130, while Goldman Sachs, Scotiabank and Bank of America also boosted their targets to the $120 region, citing resilient sales in immuno-oncology and an improving late-stage pipeline. Wolfe Research elevated its rating to “Outperform” with a $135 target. Consensus among the brokerage community now skews toward a moderate upside, with eight buy ratings, seven holds and two sells.